scutellarin has been researched along with Cirrhosis, Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, X; Guo, J; Hu, S; Jiang, S; Lan, T; Li, H; Luo, D; Piao, S; Rong, X; Tian, S; Wang, L; Wang, W; Weng, Q; Xiao, X; Yang, Y; Yu, Y; Zhang, J; Zhu, Q | 1 |
| Geng, L; Li, H; Wang, YH | 1 |
2 other study(ies) available for scutellarin and Cirrhosis, Liver
| Article | Year |
|---|---|
Breviscapine alleviates NASH by inhibiting TGF-β-activated kinase 1-dependent signaling.
Topics: Animals; Diet, High-Fat; Flavonoids; Inflammation; Lipid Metabolism; Liver; Liver Cirrhosis; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease | 2022 |
[Study on effect of scutellarin in resisting liver fibrosis in rats].
Topics: Alanine Transaminase; Animals; Apigenin; Bilirubin; Collagen Type IV; Drugs, Chinese Herbal; Glucuronates; Humans; Liver; Liver Cirrhosis; Male; Rats; Rats, Sprague-Dawley | 2015 |